The Effects Of Simvastatin On Plasm Soluble Fas And Airway Inflammation In Patients With Chronic Obstructive Pulmonary

【Objective】To observe the influence of Simvastatin on clinical symptom, Quality of life scores,pulmonary function,airway inflammation and plasma levels of soluble Fas(sFas) in patients with chronic obstructive pulmonary disease and investigate the therapeutic action of Simvastatin on COPD,Futhermore,to observe the effect of antiinflammatory action and modulate apoptosis of Simvastatin in patients with COPD in order to find the theoretical basement for the Simvastatin treatment in patients with COPD.【Methods】1.102 patients with COPD During a Stable Phase were enrolled in this study.All patients were from the clinic service of The Pulmonary Medicine of The Second Hospital of Shandong University from 2007 to 2008.2.All the patients were randomized 1:1 to receive either Simvastatin 20mg once daily(Therapy Group) or blank(Control Group)for 8 weeks.The clinical symptom scores,Quality of life scores,pulmonary function,the concentrations of TNF-αand IL-8 in induced sputum and the concentrations of sFas in blood plasma were measured before and after the treatment.32 healthy control subjects(Healthy Control Group) were enrolled in this study. 【Results】1.There were no significant differences in common data including sex,age, smoking history between COPD Group and health Control Group at baseline(P> 0.05).There were no significant differences in common data including clinical symptom,Quality of life scores,pulmonary function and levels of TNF-α,IL-8 and sFas between Therapy Group and Control group.2.Clinic symptom scoresTherapy group:The Clinic symptom scores were decreased from(5.5±1.4) to (4.0±1.2) after treatment.There were significant differences between the pre-and post-therapy(P<0.05).Control group:There were no significant differences between the pre-and post-therapy(P>0.05).There were significant differences between Therapy group and Control group after treatment(P<0.05).3.Quality of life scoresTherapy group:The SGRQ scores were decreased from(50.8±11.1) to (40.2±10.3) after treatment.There were significant differences between the pre-and post-therapy(P<0.05).Control group:There were no significant differences between the pre-and post-therapy(P>0.05).There were significant differences between Therapy group and Control group after treatment(P<0.05).4.Pulmonary functionTherapy group:There were no significant differences in FEV₁ and FEV₁(%) between the pre-and post-therapy(P>0.05).Control group:There were no significant differences in FEV₁ and FEV₁(%) between the pre-and post-therapy(P>0.05).There were no significant differences between Therapy group and Control group after treatment(P>0.05).5.TNF-α Therapy group:The concentration of TNF-αwas significant decreased from (14.71±5.04) pg·mL^-1 to(9.34±4.76) pg·mL^-1 after treatment in Therapy group(P＜0.05).Control group:There were no significant differences between the pre-and post-therapy(P＞0.05).There were significant differences between Therapy group and Control group after treatment(P＜0.05).Healthy Control Group:The concentrations of TNF-αin Healthy Control Group was significant higher than COPD Group(P＜0.05 ).6.IL-8Therapy group:The concentration of IL-8 was significant decreased from (28.97±11.21) pg·mL^-1 to(12.78±10.11) pg·mL^-1 after treatment in Therapy group (P＜0.05).Control group:There were no significant differences between before the pre-and post-therapy(P＞0.05).There were significant differences between Therapy group and Control group after treatment(P＜0.05)Healthy Control Group:The concentration of IL-8 in Healthy Control Group was significant higher than COPD Group(P＜0.05).7.sFasTherapy group:The concentration of sFas was significant decreased from (16.21±6.36) pg·mL^-1 to(13.52±5.28) pg·mL^-1 after treatment in Therapy group(P＜0.05).Control group:There was no significant difference between the pre-and post-therapy(P＞0.05)There were significant difference between Therapy group and Control group after treatment(P＜0.05 ).Healthy Control Group:The concentrations of sFas in Healthy Control Group was significant higher than COPD Group(P＜0.05) 【Conclusion】1.The clinic symptom and quality of life could be improved by Simvastatin in patients with COPD During a Stable Phase.2.The pulmonary function Simvastatin could not be improved by Simvastatin in short time.3.The concentrations of sFas,TNF-αand IL-8 were significantly higher in Therapy Group than in health Control Group(P＜0.05),The results indicate that Fas/FasL system is suppressed.4.This study indicates that statins therapy in COPD is associated with reduction of circulating markers of inflammation and accommodation cell apoptosis,it maybe supply a new drug for COPD treatment.